Focusing on Brain Health: Managing Cognitive Impairment in Primary Care Settings
Premiere Date: Wednesday, December 7, 2022This activity offers CE credit for:
%>- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- Psychological (apa)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 7, 2023
Note: Credit Is No Longer Available
Eric G. Tangalos, MD, FACP, AGSF, CMD (Moderator) Professor of Medicine Division of Primary Care Internal Medicine, Geriatrics and Palliative Care Mayo Clinic Rochester, MN |
Sharon Cohen, MD, FRCPC Behavioural Neurologist and Medical Director Toronto Memory Program Toronto, Canada |
Tatiana Sadak, PhD, PMHNP, ARNP; RN, FAAN, FGSA Associate Dean of Academic Affairs (interim) University of Washington School of Nursing Executive Director, Dementia Palliative Education Network Neurodegenerative Disorders Specialist, Psychiatric Wellness & Dementia Care Seattle, WA |
Primary care professionals (HCPs) are key to the early identification of Alzheimer’s disease (AD) and other cognitive impairments (CIs). Brain health discussions and cognitive screening are critical, as recent American Heart Association (AHA)/American Stroke Association (ASA) statements/guidelines have reaffirmed that U.S. dementia cases are estimated to triple by 2050. However, there is currently a lack of standard practice protocols for how HCPs should engage patients and families in brain health discussions and conduct cognitive assessments in primary care settings. Consequently, CI often goes unrecognized more than 50% of the time in patients age > 70, with a delay of 3 years from start of symptoms to diagnosis of AD. Clinicians should optimize discussions on brain health early and routinely and screen for CI as part of annual wellness exams to detect CI onset while mild.
Please join expert faculty for this CMEO video webcast on best practices for diagnosing CIs. The activity will include strategies for engaging patients in discussions on brain health, integrating cognitive screenings into wellness visits, employing appropriate follow-up and referral, and implementing a coordinated care approach.
At the end of this CE activity, participants should be able to:
- Integrate discussions of brain health and cognitive screenings into wellness visits with patients and caregivers.
- Employ appropriate follow-up assessment and referral for specialized diagnosis for patients with mild cognitive impairment (MCI).
- Implement a coordinated care approach within the treatment team for the ongoing management of patients with CI.
Supported by an educational grant from Genentech, a member of the Roche Group.
Physicians, PAs, NPs, nurses, pharmacists, and psychologists specializing in primary care.
ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning formats:
Enduring material
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Tangalos reports the following financial relationships:
Research Support: National Institutes of Health (NIH)
Consultant: Acadia Pharmaceuticals Inc.; Biogen; Eisai Inc.; and Genentech, Inc.
Stock Shareholder (direct purchase): AbbVie Inc.; Johnson & Johnson; and Pfizer Inc.
Other Financial or Material Support: Alzheimer's Association (Project ECHO course director); Cyclo Therapeutics, Inc. Data and Safety Monitoring Board (DSMB); and Prothena DSMB
Dr. Cohen reports no financial relationships to disclose.
Dr. Sadak reports the following financial relationships:
Advisory Board: Board of Directors, National Hartford Center of Gerontological Nursing Excellence; Board of Directors, DeTornyay Center for Healthy Aging; WA State Nursing Care Quality Assurance Commission, Critical Gaps in LTC; and WA Dementia Action Collaborative
Grants and Research Support: National Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Washington Department of Social & Health Services/Health Care Authority (WA DSHS/HCA)
Dr. Hempstead (content reviewer) reports the following financial relationships:
Financial and Material Support: Alzheimer's Association ISTAART Nonpharmacologic Intervention (Professional Interest Area Chair International); Neuropsychological Society (Chair of Continuing Education Committee); Oxford University Press (book royalties); and Soterix Medical Inc. (Licensed neuromodulation headgear device)
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WCV-058-120722-31